Pre-Open Stock Movers 09/27: (RCAT) (NKAD) (XLRN) Higher; (BHVN) (RIDE) (H) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report
September 27, 2021 6:02 PM EDTMerck & Co., Inc. (NYSE: MRK) is nearing a deal to acquire Acceleron Pharma Inc. (NASDAQ: XLRN), in an agreement that could be completed as soon as this week, The Wall Street Journal reported citing people familiar with the... More
Acceleron Pharma (XLRN) $180/Sh Rumored Takeover Price 'Too Low' - Cowen
September 27, 2021 1:22 PM EDTCowen analyst Yaron Werber weighed in on Acceleron Pharma (NASDAQ: XLRN) following reports the company is in advanced talks to be acquired for $180/share. Werber sees that price as "too low" to get a deal done.
"If true, we believe... More
